POELLATH advises NVision Imaging Technologies GmbH on series A equity financing round of USD 30 million
Both existing investors and new investors participated in the financing round such as renown venture capital investors from the US, Israel, Luxemburg, Portugal and investment companies of German regional banks in order to support NVision Imaging Technologies on their mission to build systems enabling metabolic imaging for adaptive cancer treatment.
NVision Imaging Technologies GmbH is an Ulm-based award-winning Deep Tech startup with more than 50 employees from more than 10 countries. The company was founded in 2015 and leverages advances in quantum physics to facilitate the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level. NVision plans to deploy its Polarizer systems at more than 50 cancer centres worldwide by 2025.
POELLATH is NVision’s ongoing legal advisor since NVision’s beginnings. In this series A financing round, POELLATH advised NVision with the following Munich team: